Are you the publisher? Claim or contact us about this channel

Embed this content in your HTML


Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog

Channel Description:

Biotechnology Forums -

(Page 1) | 2 | 3 | .... | 119 | newer

    0 0

    Greiner Bio One, located in Monroe North Carolina has taken into consideration a change in the marketing regarding biotechnological products. A major distributor of Roller Bottles has discontinued their production and Greiner Bio One has decided to ramp up our production in an attempt to fill the need for customers.

    I would be very interested to know exactly what experiments/research CELLSTAR Roller Bottles are being used for and what problems have you experienced with their use?

    Mackenzie Farone

    0 0

    Hello everyone, I am currently a senior in high school researching careers in biotechnology. I am planning to attend BYU. It offers an undergraduate program in "Genetics & Biotechnology: Business track" or "Bioinformatics". I was hoping to get some perspectives on which degree is more practical, and what kind of person these degrees would suit.

    I am debating between these two degrees as I am interested in both the business/industry and computer science aspects of biotechnology. Thanks for your help.

    0 0

    cows produce beef and milk. but take a time to think, how about if cows are consumed by us (the beefs), how many are killed? a cow has reproduction time is about 7-8 months, but we consumed it everytime. the solution of this problem is using genetic engineering. the genetic engineering that makes mysostatin gene is deleted. first of all, myostatin is a gene that regulate muscle (size etc) not only in cows but also in humans.

    when we deleted this gene, a muscle growth become uncontrol-able. they are getting bigger. some cows are using this genetic engineering by selective breeding. that's why we are still 'safe' whether we consumed beefs from this selective breeding cows.

    in some human, the case about myostatin which is deleted is become 'mutant'. they are still human, but with a big muscle and hyperactive. the negative side in human, they can cause many diseases like premature or kidney's abnormal (the size is bigger than usual).

    in cows, the deleting of myostatin gene makes the meat became more lean, because fats are deposition into a meat.
    for more information you can watch :

    so, we can save our money and no more cows to be killed.Smile

    0 0

    Hello all. I'm an MSc student working on the vitamin D receptor gene in human monocytes, and micro RNA. My colleague and I have been struggling to find suitable refernce genes, as we find that all those we are using amplify pseudogenes. Can anyone give me advice on which genes I can amplify as reference genes, and any sequences? Thank you

    0 0
  • 07/11/11--06:25: guidance
  • i m doing Int. biotechnology (5yr course). i want 2 knw dat wat will b d better option- job or further studies like phd/ mba..and why????

    0 0

    Hi Biotech Folks,

    I am working with 3M's Life Science Process Technologies Division to get a better idea about the online habits of engineers in the bio-process industry. We are really interested in knowing more about your community and what makes you tick. Would anyone be interested in participating in this short survey?

    The survey will only take a few minutes to complete, all answers will be kept anonymous and your personal information will not be shared with anyone. All participants will receive a gift card for their time.

    To complete the survey click here. At the end of the survey you can submit your email address and we’ll send you your electronic gift card.

    3M Questionnaire - PI Survey

    0 0
  • 07/13/11--09:48: guidance
  • I'm currently doing M.Tech Industrial Biotechnology(5yr Integrated) and i like to know about the PhD(Industrial Biotechnology) opportunities in Europe and also employment opportunities in India and abroad.
    Thank you.

    0 0
  • 07/17/11--20:33: Horticulture Happenings
  • I am offering a continuing education course titled, “Plant Biotechnology and You,” on Wednesday, August 3 from 6:30 to 9 PM at KCC’s campus. During this discussion-based course I will introduce the basic science and concepts behind plant biotechnology using examples of where plant biotechnology crosses your everyday life. A portion of this discussion will be devoted to the moral and ethical implications of plant biotechnology. The topic will be approached in a scientific manner and all viewpoints are welcome. For more information, check out: Contact KCC Continuing Education at 815-802-8206 to register for this course.

    0 0
  • 07/27/11--16:21: Stem Cell Resources
  • Stem Cell Basics

    Stem cells, by definition, can undergo infinite number of cell division while remain in an undifferentiated state. However, they can also give rise to differentiated daughter cells that are committed to specialized cell fate in all three primary germ layers: ectoderm, mesoderm and endoderm. During embryogenesis, the degree of this differentiation becomes gradually restricted as the fetus develops and the potential of various stem cells is limited by the class they belong to. While both totipotent and pluripotent stem cells can generate every type of cells found in the body, only totipotent ones are able to form an entire organism. In contrast, multipotent stem cells are more mature in developmental age compared to totipotent and pluripotent stem cells, and therefore, can only give rise to a limited population of cells within a specific lineage.

    The particularly extrinsic and intrinsic molecular signaling network that confers their self-renewal and differentiation remain fairly uncharacterized. However, a consistent requirement for the Oct4, Nanog and Sox2 transcription factors in maintaining pluripotency seems to be evolutionarily conserved between mouse and human.

    0 0
  • 08/03/11--01:07: Biotech-Pharma Deal
  • Dear all,

    I am currently pursuing some market research regarding the synergy between Biotech and Pharma companies in pre-clinical stage deals and hence in the process of building a financial model. The recent Rib-x-Sanofi deal is a prime example.

    The questions that I have are as follows:

    1. What is the peak sales assumed for antibiotics and in how many years?
    2. What are the royalty percentage we are looking at and is it on a tier basis?
    3. What is the market trend for such pre-clinical stage deals?
    4. Is all the upfront payment given in cash as widely reported or there are clauses attached to it?
    5. What sort of discount rate do we use to value such deals?

    Any help in this regard will be much appreciated.


    0 0

    Western blotting…*sigh*…I have been performing Western blots on my peptides which are labelled with both a GST tag and a HIS tag on their N- and C-terminal ends respectively. Whenever I perform the blot with an anti-GST antibody, it works perfectly, yet whenever I perform the blot with the anti-HIS antibody, it never works properly. My samples would never appear, and my controls would be faint. I cleaved the GST tag from my peptides (with Thrombin, stopping the reaction with PMSF) and then performed a blot with the anti-HIS antibody again, and now nothing shows up, only non-specific blotches all over the exposed film!

    If anyone has any suggestions as to what might be interfering with it, I’d greatly appreciate it. Thanks Big Grin

    FYI, I have also posted this discussion on Nature Network.

    0 0
  • 08/08/11--10:09: Career Guidance for Biotech
  • Hi,

    I wanted to get anyone's advice or suggestions on how to get my foot in the door of biotech companies. I have several years of research experience in the field of oncology, heart disease, autoimmune, and mental disorders. However, many biotech positions (shooting for Bay Area companies) require experience directly in the field of biotechnology. Does anyone have any thoughts? Thanks so much for your time!

    0 0


    ‘JanuGanak’ - Bioinformatics Community of Department of Biotechnology and Bioinformatics, Padmashree Dr. D Y Patil University, is pleased to inform you that a two days national workshop on ‘MOLECULAR DOCKING AND VIRTUAL SCREENING ’ is being organized. This workshop is the third of a series of workshops which are aimed at giving complete hands-on experience in various tools and techniques used in the field of Life Science and Bioinformatics.

    This session is aimed at giving practical experience on the basic methods of modeling of protein structures, sketching of ligands, docking and virtual screening using bioinformatics tools. Both under-graduate and post-graduate students can participate in this workshop.

    Interested candidates from Research Fraternity as well as faculties from various areas of Life Sciences are also welcome. We hope that this workshop will provide fairly good amount of knowledge about Molecular
    Modeling, Docking, Sketching of Ligands, and Virtual Screening which is essential in all fields of Life Sciences today.

    Venue – Level VI
    Department of Biotechnology and Bioinformatics,
    Padmashree Dr. D. Y. Patil University,
    Plot 50, Sector 15, CBD Belapur, Navi Mumbai-400614

    Date – 14th and 15th October 2011

    Time - 10.00 AM to 5.00 PM

    Contents -
     Sequence to Structure - Homology modeling
     Sketching of Ligands
     Docking Studies
     Virtual Screening

    Registration Fees – Rs. 1000/- per candidate

    Mode of Payment – Cash or DD / Cheque in favor of “Pad Dr. D. Y. Patil University, Dept. of Biotechnology & Bioinformatics”

    Total Number of Seats – 40 (First-cum First-Serve basis)

    Last Date of Registration – 8th October, 2011

    Registrations are done at the above mentioned venue. Participants can also obtain the electronic copy of the Registration Form by contacting at the email address given below or can download from the conference section at

    Registration fees should accompany the duly filled registration form with a passport – size photograph.

    For further enquiries contact –Mr. Sagar Nagare (9595750057), Mr. Pramodkumar Gupta(9323250900)

    Mail –

    0 0
  • 09/28/11--20:06: Conference
  • Dear {First Name}

    How do you know that your computational model is right? Please attend to this International Computational Modeling Conference in Sydney, Australia.

    Please see here the details:

    Please note that there will be advanced training of few software as post conference Trainings:

    If you would like to nominate yourself or anyone else as a Keynote speaker, please register here:

    Please nominate yourself and others as reviewers if interested:

    About Sydney, please visit:

    For sponsorship deals and many others, please visit:

    We would like you to spread the news as time is limited. Few journals will accept selected papers for publication. Please contact for an updates.


    Engineering Event Management Division
    Don Computing


    fax: 61-2-94754512



    International Conference in Sydney, Australia: 13-14th January 2012
    Don Computing is hosting “International Computational Modeling Validation Conference” in Sydney, 13-14 January 2012. Australian Technology Park, Sydney, Australia

    read more »

    Who Should Join?

    Academics, Researchers, Industrial Engineers, Scientists, Students, CFD/FEA/Process Modeling/Reservoir Simulation users, Computational modeler, managers.
    Oil and gas, Aerospace & Maritime, Automotive & Transportation, Environmental Flows-Water, Environmental Flows – Atmospheric, Air-conditioning & Industrial Ventilation, Turbo machinery, Pumps & Appliances, Combustion & Power Generation, Biomedical Flows, Chemical & Process, Electronics & Semiconductors, Food & Beverage, Mineral Processing, Refining & Smelting.

    read more »

    Why Should you Join?

    Collaboration with Big Companies
    Get an Efficient solution of your industrial problems
    Sign agreement with Don Computing to offer consulting to many industries
    Selling your expertise to the world through Don Computing
    Learn how to validate your computational model
    Learn about the latest development in Software for CFD/FEA/Process Modeling/Reservoir Simulation
    Expand the business with more clients
    Tell the world about your offer
    Plan for the future growth

    read more »

    Why Sponsor an Event?

    Sponsorship of an event will make your company stand out as a leader in this burgeoning industry and will leave a strong impression of your brand in people’s minds. Sponsors have an incredible amount of presence and in conjunction with an exhibition stand it will not only give your company optimum exposure but also the opportunity for delegates to meet you and your Executives to find out more about your role and business opportunities in the sector.

    Networking with the industries leading Government Officials, Senior Level Delegates and Experts
    Access to interact with Senior Business Partners
    Get an Efficient solution of your industrial problems
    Learn how to validate your computational model
    Learn about the latest development in Software for CFD/FEA/Process Modeling/Reservoir Simulation

    For sponsorship deals and many others, please visit:

    Letter from the Organiser
    September 2011

    Keynote Speaker 1. Dr Thomas Höhne: Recent Developments in CFD Modelling of Multiphase Flows

    Dr. Höhne studied Thermal Engineering at the Department of Mechanical Engineering at the Technical University of Dresden/Germany. Since 1997 he is working at the Safety Analysis Department in the Institute of Safety Research at Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Germany in the field of numerical simulation of coolant flow and mixing and obtained in this field his Ph.D. (2003). His newer activities comprise CFD-analyses in buoyancy driven natural circulation phenomena and stratified horizontal two-phase flow processes. Today he is head of the international CFD research group at the Institute of Safety Research at HZDR. Due to the leading position in the analysis of the coolant mixing, Dr. Hoehne took part as a Senior Expert in an EU project on the coolant mixing for Russian pressurized water reactors and works now as an expert in an industrial project of VGB (Association of major German energy companies) as a project manager.

    Keynote Speaker 2. Dr Neihad Al-Khalidy: Engineering Solution for Industrial thermo/fluid problems

    Dr. Neihad has more than 15 years experience in CFD and FEA, awarded a PhD from Europe, worked for Worley Parsons, UNSW and now with the SLR consulting. Dr. Neihad has managed many industrial and commercial projects throughout Australia, SE Asia and the Middle East in the fields of CFD, Analytical Calculation (Building Facades, Condensation and Insulation Assessment), Ecologically Sustainable Development, Building Energy Rating, Exterior Lighting, Solar, Reflectivity and Overshadowing, Acoustically Induced Vibration and Pulsation Assessment. Recent projects include assessments associated with the Sydney Airport, Westfield Liverpool, Westfield Bondi Junction, Penrith Plaza, Macarthur Square, Top Ryde Shopping Centre, Parramatta Shopping Centre Redevelopment, Mawson Lakes School in Adelaide (This building received the Sustainable Building RAIA Awards), Australian science building in Adelaide, Melbourne Central, Forestry SA, Wind, natural ventilation and carpark air quality of Claremont Village in Perth, Natural Ventilation Design and air quality assessment of IKEA Building carpark in Perth.

    0 0

    Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies. The data analyzes global and regional market performances, trends, facts, market sizes, market shares, market entries, demand, supply, forecasts, market outlook, competitive intelligence, and other informative statistics and data analytics - critical information necessary for effectively competing in the marketplace.

    Our reports may help strategists, investors, laboratories, contract research organizations, biotechnology & Healthcare companies, academic professionals, drug approval authorities, and other organizations in -

    * Gauging Competitive Intelligence
    * Identifying Key Growth Areas and Opportunities
    * Understanding Geographic Relevance to Product
    * Knowing Regional Market Sizes and Growth
    * Opportunities and Restraints
    * Keeping Tab on Emerging Technologies
    * Equity Analysis
    * Tapping New Markets

    Analytics and data presented in each report pertain to several parameters such as –

    * Global and Regional Market Sizes, Market Shares, Market Trends
    * Product (Global and Regional) Market Sizes, Market Shares, Market Trends
    * Technology Trends
    * Corporate Intelligence
    * Key Companies By Sales, Brands, Products
    * Consumer Behavioral Patterns
    * Other Strategic Business Affecting Data

    0 0

    Ken Aldrich said, "Last week's newspapers carried the news of what was widely described as a significant “breakthrough” in stem cell science: the first successful human use of a technology known as Somatic Cell Nuclear Transfer (also referred to as SCNT). This is essentially a variation on a process that was used some years ago to create a cloned sheep named Dolly. Cloning has since been used commercially in various animal applications.

    What is strange about the flurry of publicity about this discovery, however, is the almost total lack of commentary about a method of creating stem cells that has been available to researchers for almost half a decade, holds the same kind of promise as embryonic stem cells for providing cells for the treatment of almost any kind of degenerative disease, is free of ethical issues (including issues with egg donation), and can potentially make immune matched cells available to any patient anywhere in the world, on demand, at a far lower cost.

    I am talking about human stem cells derived from a process called, “Parthenogenesis”, developed and first announced in 2007 by a company called International Stem Cell Corporation, whose discoveries were first published in the peer reviewed journal, Cloning and Stem Cells, edited by the scientist who first created “Dolly”, the first cloned animal.

    I realize that I could be accused of bias because I am one of the founders of International Stem Cell, but, in fact, our company also owns license rights to some of the key intellectual property that is required to create cells through SCNT technology and our scientists are very familiar with its promise and its limitations. As a result, International Stem Cell will benefit from the development of either technology, but it is important that the public and the scientific community be fully aware of all alternatives in the field of regenerative medicine, not just the ones that capture public imagination at any particular time.

    For that reason, I would like to comment on Parthenogenesis and compare it to SCNT technology and the other options available today. The technology known as "Parthenogenesis" begins with human eggs that are created and used every day throughout the world for in-vitro fertilization (IVF). What is not generally known is that the IVF process can often result in the creation of far more unfertilized eggs than will ever be needed for fertility purposes. It is possible, with informed consent from the IVF patient, to hold back some unfertilized eggs for creation of parthenogenetic stem cells, all at no additional risk to the donor.

    Instead of wasting those eggs, what International Stem Cell does, with the full consent of the donors, is to save those eggs from the trash bin, induce them through a simple, but patented, process to create the small cluster of cells from which a stem cell line can be created that can be used for scientific research and the eventual treatment of patients with such diseases as Parkinson’s, Macular Degeneration, Liver Disease, Diabetes, and possibly many others.

    What are critical to understand in thinking about Parthenogenetic stem cells are six things:
    Like embryonic stem cells and SCNT cells, these cells can be converted into almost any cell in the human body and thus have enormous potential for human therapy.

    Unlike embryonic stem cells, the human eggs used to create parthenogenetic stem cells are never fertilized and cannot become a human being. No viable embryo is ever harmed or destroyed.

    Unlike SCNT cells, parthenogenetic stem cells require no genetic manipulation or insertion of foreign DNA.

    No donor is every subjected to any additional physical risk beyond what she has already agreed to as part of the IVF procedure in which she elected to participate. In fact, all egg donors voluntarily participate through a very transparent, peer-reviewed, and medically supervised process. Protocols are approved by Independent Review Boards (IRBs) to protect the safety of donors and by an independent Stem Cell Research Oversight (SCRO) committee to insure compliance with state laws and research ethics, regulations established by the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services (HHS) Office for Human Research Protections, in addition to state-level requirements.

    The cell lines that are produced from this method, unlike cell lines from embryonic stem cells or from SCNT, can potentially be matched to millions of people in the same way that an organ transplant is matched between donor and patient. In fact, by some estimates, as few as 100 parthenogenetic stem cell lines could provide immune-matched cells to over 50 percent of the world’s population, and could accelerate disease therapies and treatments for severe chronic conditions, including diabetes, spinal cord injuries, liver diseases, blinding diseases such as macular degeneration, and neural diseases such as Parkinson’s and Alzheimer’s.

    The possibility of immune-matching to millions of persons can vastly reduce the potential costs relative to SCNT or embryonic stem cell technology, which create stem cell lines that can match only a few persons.

    In summary, what we find particularly exciting about Parthenogenesis is that it addresses all the major issues of stem cell therapy. It is free from the traditional bioethical issues that have clouded federal policies towards stem cell research because parthenotes are derived from unfertilized eggs and cannot develop into human beings. Parthenogenesis is not cloning, and it does not involve the creation or destruction of a viable human life. Also, the creation of a parthenogenetic stem cell bank will not require a large number of human eggs and many individual donors, as has been a fear surrounding other stem cell approaches. Parthenogenesis is at once effective and efficient, and one line of parthenogenetic stem cells can be used to create treatments for millions of persons. This is not a situation where one line must be made for each patient treated."

    0 0

    I need the entire genome sequence of Clostridium thermocellum or at least the gene that allows the microbe to degrade cellulose. Any suggestions?


    "The mind is everything, what you think you become."

    0 0

    Dear All,
    I would like to ask a question about how a genetic disorder can affect the birth of third generation in a family?
    To elaborate, for e.g ; a boy's family (father's side) has a background of genetic disorder (2 cases where a child is born with an immature brain as per age). If he marries a girl having no such background of genetic disorder, then what are the chances of this disorder getting evolved to the child of this couple?
    I dont know whether i have framed the question correctly as I dont have a background of medicine and science. I am into Human Resource field. I am registered in this forum just to ask this question to the people who have quite a good exposure into this field.
    Please help as it can help me take a decision of life....
    Thank you very much in anticipation.

    Reshma Vohra

    0 0

    Network Modeling and Analysis in Health Informatics and Bioinformatics (NetMAHIB)
    Published by Springer
    Reda Alhajj
    University of Calgary

    Dear Colleague,

    You are invited to consider “Network Modeling and Analysis in Health Informatics and Bioinformatics” Journal, (NetMAHIB) as the main outlet for your high quality research papers. The NetMAHIB journal provides a rapid forum for the dissemination of original research articles in all areas of health informatics and bioinformatics.

    The journal website may be accessed at:

    Aims and Scope

    NetMAHIB publishes original research articles and reviews reporting how graph theory, statistics, linear algebra and machine learning techniques can be effectively used for modelling and knowledge discovery in health informatics and bioinformatics. It aims at creating a synergy between these disciplines by providing a forum for disseminating the latest developments and research findings; hence results can be shared with readers across institutions, governments, researchers, students, and the industry. The journal emphasizes fundamental contributions on new methodologies, discoveries and techniques that have general applicability and which form the basis for network based modelling and knowledge discovery in health informatics and bioinformatics.

    The NetMAHIB journal is proud to have an outstanding group of editors who widely and rigorously cover the multidisciplinary score of the journal. They are known to be research leaders in the field of Health Informatics and Bioinformatics. Further, the NetMAHIB journal is characterized by providing thorough constructive reviews by experts in the field and by the reduced turn-around time which allows research results to be disseminated and shared on timely basis. The target of the editors is to complete the first round of the refereeing process within about 8 to 10 weeks of submission. Accepted papers go to the online first list and are immediately made available for access by the research community.

    We look forward to receiving your submissions online:

    Topics covered by NetMAHIB include but are not limited to cutting-edge and novel findings on the latest trends and developments in network modelling and analysis for knowledge discovery in health informatics and bioinformatics, encompassing areas such as:

    · Clinical and hospital human resource management and performance analysis

    · Controlled and optimized utilization of resources

    · Modelling, simulation and evaluation of healthcare services

    · Patient tracking and monitoring

    · Spread and control of epidemics

    · Drug design, disease diagnosis and control

    · Signal pathways and cell control

    · Metabolic pathway and regulatory network modelling, evolution, simulation, analysis, control and engineering

    · Modular biology and systems biology

    · Computational biomedicine, genomics, proteomics, transcriptomics, metabolimics, sociogenomics

    · Social network modelling and analysis in health informatics and bioinformatics

    · Future developments in technologies and applications

    0 0

    hi there

    My background isn't in science. More in science fiction.

    But someone has to visualise the future before it is made fact. E.g. Arthur C. Clarke and the communications satellite.

    I'm disturbed by the lack of vision regarding the energy sources which will replace fossil fuels.

    So here's an extreme vision for the future. Is it viable?

    1. Electricity will be generated by custom made organisms.

    2. Houses will be lit by slime painted on the walls, containing the same light emitting cells as are present in deep sea organisms.

    3. Houses will be heated by over-sized GMO hearts, pumping warm blood around a radiator system, and fed on food waste.

    So there's the vision. But is it possible? Electric eels generate power. Lemons can light a bulb. Can these properties be enhanced a millionfold, then utilized in our daily lives?

    If they can, perhaps we can sidestep future Fukushimas?

    Thanks for looking. I'm feeling pretty humble here, as my only science degree is in the social sciences.


(Page 1) | 2 | 3 | .... | 119 | newer